how long does glp 1 vomiting last GLP-1 Nausea Guide: to Calm Your Gut and Stay on Track Managing Side Effects of GLP-1

In 2024 semaglutide (Wegovy) became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular (CV) disease and obesity and overweight

The research on subtherapeutic doses is limited, and long-term effects remain unknown

Flow Wellness can evaluate potential causes such as inadequate protein intake, insufficient exercise, medication dosing, hormonal imbalances, poor sleep, or metabolic adaptation

The SURMOUNT-5 trial directly compared the two medications and found tirzepatide produced approximately 20 percent weight loss compared to 14 percent for semaglutide

But thats not true for everyone

J Diabetes Investig 2025;16:183-6.ArticlePubMed 105